HOME >> BIOLOGY >> NEWS
Drugs limit deadly side effects of graft-versus-host disease

aft-versus-host disease each year

"An allogeneic bone marrow transplant is a double-edged sword," says Pavan Reddy, M.D., an assistant professor of internal medicine in the U-M Medical School and corresponding author of the PNAS paper. "The good side is the graft-versus-leukemia (GVL) effect, which means that T cells from donated bone marrow, called the graft, will attack and kill any cancer cells remaining in the patient. GVL represents the most potent known form of immune therapy against malignant diseases. Without GVL, the cancer will most likely return.

"The bad side is graft-versus-host disease. In GVHD, T cells from donated bone marrow, in concert with inflammatory cytokines, attack the patient's skin, liver and gastrointestinal tract," Reddy explains. "The key is to block the inflammatory cytokines, which exacerbate GVHD, but leave the cancer-killing donor T cells untouched, since they are vital for an effective GVL response."

In previous research published in the June 2002 issue of Nature Medicine, Ferrara and Reddy, with colleagues from the U-M Cancer Center, discovered that inflammatory cytokines are the major cause of GVHD-induced cell damage. Since then, they have been searching for ways to neutralize cytokines or block their production. Their current work with HDAC inhibitors is an extension of this earlier research.

"No one has looked at this class of drugs in a post-bone-marrow-transplant setting before, but two other groups have found similar anti-inflammatory effects in mouse models used for research on lupus and sepsis," says Reddy. "So now there are several studies showing that HDAC inhibitors are more than just anti-tumor agents."

Reddy and his U-M research colleagues conducted two sets of experiments with strains of laboratory mice commonly used in research related to bone marrow transplants. In the first experiment, three groups of mice were given standard bone marrow transplants. Mice received bone marr
'"/>

Contact: Sally Pobojewski
pobo@umich.edu
734-615-6912
University of Michigan Health System
27-Feb-2004


Page: 1 2 3 4 5

Related biology news :

1. Drugs, electronics, and green catalysts: The chemical year in review
2. Drugs from sea study finds sponge health link to bacteria
3. Drugs on tap
4. Discovery Of A Molecule That Controls Bile Acids May Lead To New Cholesterol Drugs
5. UT Southwestern Researchers Find Way To Control Gene Activity, Opening Way For Cancer Drugs
6. New Findings On Receptor Regulation May Lead To Better Drugs For Diabetes
7. NASA Research Helps Map Protein Structures -- Key In The Development Of New Disease-Fighting Drugs
8. 15 Drugs, Dyes And Other Chemicals Newly Listed As Known Or Likely Human Carcinogens
9. Cholesterol Lowering Drugs Stall Disease Progression In People With Below-Average Blood Cholesterol Level
10. Some AIDS Patients May Show Resistance To Sulfa Drugs
11. Researchers Discover Existing Drugs May Prevent Enlarged Hearts

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Drugs limit deadly side effects graft versus host disease

(Date:8/6/2015)... , August 6, 2015 ... (SMI) shows the world,s first Eye Tracking Integration ... Moverio BT-200 see-through head mounted display and on SMI,s ... quality and efficiency is brought to personalized visualization and ... first time, professionals and researchers can integrate gaze, and ...
(Date:8/5/2015)... August 5, 2015 According to ... Management Market by Software, Services, Vertical (BFSI, Airport, IT & ... - Global Forecast to 2020", published by MarketsandMarkets, defines ... globally into various segments. The global PIAM Market is ... $546.2 Million by 2019, at a CAGR of 14.9 ...
(Date:8/5/2015)... VIEW, Calif. , Aug. 5, 2015 ... exhibits continuous growth in applications, penetration into newer sectors, ... after year. The global biosensors space has seen the ... exited the market so far. (Photo - ... Frost & Sullivan, Analysis of the Global Biosensors ...
Breaking Biology News(10 mins):SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
(Date:9/1/2015)... 2015 Shire plc (LSE: SHP, NASDAQ: ... to its Board of Directors as a Non-Executive Director. ... & Risk Committee of the Shire Board. Both appointments will ... previously served as Chairman, President and Chief Executive Officer of ... her 12-year tenure at D&B, she helped drive the transformation ...
(Date:8/31/2015)... 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... are for air emission abatement projects in North ... large order for a municipality in the Southern ... competitor,s system that failed to meet the customer,s requirements. This demonstrates ... Derek S. Webb , President and Chief Executive Officer.  ...
(Date:8/31/2015)... , Aug. 31, 2015 MabVax Therapeutics Holdings, ... announces that the Company,s lead antibody, HuMab 5B1, will ... separate presentations during the upcoming World Molecular Imaging Congress ... September 2-5, 2015. Researchers from the Department of Radiology ... results on the use of MabVax,s lead antibody as ...
(Date:8/31/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/k6lcp2/mexico_biomedical ) ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Mexico Biomedical Sensors market is estimated at $0.20 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
Breaking Biology Technology:Shire Appoints Sara Mathew to Board of Directors 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4Mexico Biomedical Sensors Market Report 2015-2020 2
Cached News: